Related Experiment Video
Updated: May 6, 2026
Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
Published on: August 11, 2015
Comparative Efficacy of Perioperative Blood Conservation Agents in Pediatric Cranial Vault Remodeling: A Systematic
Christopher C Padilla1, Michael Farid1, Parker Smith2
1Weill Cornell Medical College, Cornell University, New York , New York , USA.
Insights
Perioperative blood conservation agents like tranexamic acid (TXA) and aminocaproic acid (ACA) significantly reduce red blood cell transfusions in pediatric cranial vault remodeling. Combination therapies, particularly TXA + EPO + iron, show the greatest efficacy.
Area of Science:
- Pediatric Surgery
- Anesthesiology
- Hematology
Background:
- Red blood cell transfusions are common in pediatric cranial vault remodeling (CVR) but carry risks.
- Optimizing transfusion management is crucial for patient safety and outcomes.
Purpose of the Study:
- To evaluate the efficacy of perioperative blood conservation agents in pediatric CVR.
- To identify agents that optimize and reduce transfusion requirements.
Main Methods:
- Systematic review of studies on blood conservation agents in pediatric CVR.
- Network meta-analysis comparing tranexamic acid (TXA), aminocaproic acid (ACA), aprotinin, erythropoietin (EPO), and iron.
Main Results:
- TXA and ACA independently reduced transfusion rates and volumes compared to placebo.
- Combination therapies (TXA + EPO + iron, ACA + EPO) showed significant reductions in transfusion rates.
- TXA + EPO + iron also reduced hospital length of stay; no agent affected surgery duration or caused thromboembolic events.
Conclusions:
- Combination therapies, especially TXA + EPO + iron and ACA + EPO, are highly effective in reducing red blood cell transfusions in pediatric CVR.
- Multimodal protocols incorporating these agents are recommended for perioperative blood conservation.
Background And Objectives:
Red blood cell transfusions are commonly required in pediatric cranial vault remodeling (CVR); however, they carry risks and potential complications. This study evaluates the evidence on perioperative blood conservation agents assessing their efficacy in optimizing and reducing transfusion requirements in CVR.
Methods:
A systematic review was conducted using PubMed/MEDLINE, Scopus, Embase, Web of Sciences, and Google Scholar according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to assess articles discussing blood conservation agents in pediatric CVR. A network meta-analysis compared the effectiveness of different agents including tranexamic acid (TXA), aminocaproic acid (ACA), aprotinin, erythropoietin (EPO), and iron.
Results:
Sixteen studies analyzing 1072 patients with a mean age of 15.6 months and weight of 8.78 kg were included. The most reported craniosynostosis subtypes were sagittal (30.2%) and metopic (13.8%). TXA and ACA were independently associated with lower transfusion rates and volumes compared with placebo (ACA: odds ratio [OR], 0.25; 95% CI, 0.08-0.80; TXA: OR, 0.17; 95% CI, 0.07-0.42). Combination therapy with TXA + EPO + iron (OR: 0.004, 95% CI: 0.002-0.10) or ACA + EPO (OR: 0.04, 95% CI: 0.01-0.32) were associated with reductions in transfusion rates. Network meta-analysis ranking revealed TXA + EPO + iron (Surface Under the Cumulative Ranking [SUCRA]: 98.90%) and ACA + EPO (SUCRA: 75.41%) as the most effective treatments for reducing transfusion rates. While TXA was associated with significant reductions in blood loss compared with placebo (standard mean difference: -1.26, 95% CI: -1.97 to -0.56), ACA ranked highest for blood loss reduction (ACA: SUCRA, 84.58% vs TXA: SUCRA, 72.43%). Combination of TXA + EPO + iron was associated with significantly reduced hospital length of stay (standard mean difference: -1.00, 95% CI: -1.71 to -0.29). No treatment significantly affected the duration of surgery, and there were no reported treatment-associated thromboembolic events.
Conclusion:
Our meta-analysis reveals that TXA + ACA reduce red blood cell transfusion rates and volumes, with TXA + EPO + iron and ACA + EPO being most effective. This highlights the superiority of combination therapies and underscores the need for structured multimodal protocols in perioperative blood conservation for pediatric CVR.
